AbbVie's Parkinson's drug Duopa OK'd in US
This article was originally published in Scrip
AbbVie disclosed on 12 January the FDA had approved Duopa, an enteral suspension formulation of carbidopa and levodopa, as a treatment for motor fluctuations in patients with advanced Parkinson's disease.
You may also be interested in...
AbbVie has added Mission Therapeutics to its preclinical partnership roster with a neurology deal to develop DUB inhibitors in Alzheimer’s and Parkinson’s disease.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.